Ricarda Hinzpeter1, MD; Matthias Eberhard1, MD; Alberto Pozzoli2, MD; Jochen von Spiczak1, MD, MSc; Robert Manka1, MD; Felix C. Tanner3, MD; Maurizio Taramasso2, MD; Francesco Maisano2, MD; Hatem Alkadhi1, MD, MPH, FESER, EBCR
1. Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; 2. Department of Cardiovascular Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland; 3. Department of Cardiology, University Heart Center Zurich, University of Zurich, Zurich, Switzerland
Introduction
Mitral regurgitation (MR) represents one of the most common valvular heart diseases affecting almost 10% of the population >75 years of age1. According to the American College of Cardiology/American Heart Association, surgical interventions still represent the gold standard for treatment of severe MR2. However, many patients do not undergo surgery due to increased surgical risk, which has driven the field of percutaneous mitral valve (MV) treatments, including repair and replacement technologies3. As catheter-based MV repair options are increasingly adopted in clinical practice, they require accurate preprocedural imaging, providing detailed anatomic information about the MV and adjacent structures ...
